Borgia SM, et al. - In patients with hepatitis C virus (HCV) infection with end-stage renal disease (ESRD) undergoing dialysis, researchers tested the safety and effectiveness of sofosbuvir/velpatasvir. Open-label sofosbuvir/velpatasvir (400 mg/100 mg) once daily for 12 weeks was given to 59 patients with genotype 1-6 HCV infection with ESRD undergoing hemodialysis or peritoneal dialysis in this phase 2, single-arm study. SVR12 was accomplished in 56 out of 59 patients in patients with ESRD undergoing dialysis; treatment with sofosbuvir/velpatasvir for 12 weeks was safe and effective. Headache, fatigue, nausea, and vomiting were the most common adverse events.